Gilead Sciences (GILD) Announces New Results From a Post Hoc Analysis

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best inexpensive stocks to invest in right now. Gilead Sciences, Inc. (NASDAQ:GILD) announced on May 27 new results from a post hoc analysis that showed that Livdelzi® was associated with high and sustained rates of normalization of a key liver marker in people living with primary biliary cholangitis. The company reported that participants with increased ALP levels in an ongoing Phase 3 study experienced reductions in ALP after treatment, and the data showcase the potential role of Livdelzi in people with PBC who continually have elevated ALP despite prior treatment with first-line therapy.

Morgan Stanley Reassesses Gilead Sciences (GILD) Outlook Following Quarterly Report

Gilead Sciences, Inc. (NASDAQ:GILD) stated that the findings are “highly relevant” for people living with PBC with inadequately controlled disease based on elevated ALP levels, as that is a population that is historically underrepresented in randomized clinical trials. The company would present the data at the European Association for the Study of the Liver (EASL) Congress 2026, held May 27–30 in Barcelona, Spain.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19. Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others.

While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1